Skip to content
Translational Neuropharmacology Lab (Zanos Lab)

Translational Neuropharmacology Lab (Zanos Lab)

Our laboratory, based in Cyprus, employs molecular and systems neuroscience, behavioral pharmacology, as well as advanced computational methods to unravel the mysteries of brain diseases and identify targets for the development of novel and effective pharmacotherapies.

Menu
  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Author: admin

Novel Computational Framework Reveals EBV’s Role in Multiple Sclerosis Presented at 15th International Conference of the Center for Applied Neuroscience

No Comments
| News

Novel Computational Framework Reveals EBV’s Role in Multiple Sclerosis Presented at 15th International Conference of the Center for Applied Neuroscience We are proud to announce that our Senior Researcher Dr. Anna Onisiforou presented groundbreaking research on the role of Epstein–Barr virus (EBV) in Multiple Sclerosis (MS) at the 15th International Conference of the Center of […]

Read More »

Dr. Zanos Moderated Symposium on Non-Invasive Neuromodulation at 15th International Conference of the Center for Applied Neuroscience

No Comments
| News

Dr. Zanos, served as moderator for the invited symposium session titled “Non-Invasive Neuromodulation: Current State and Future Directions” at the 15th International Conference of the Center for Applied Neuroscience, held at the University of Cyprus. The session featured international speakers who are leading experts in the field of neuromodulation and brain stimulation: Professor Alexander T. […]

Read More »

PROUD Project Presented at the 15th International Conference of the Center for Applied Neuroscience

No Comments
| News

We are pleased to announce that our Ph.D. student Morfeas Koumas presented our “PROUD” project at the 15th International Conference of the Center of Applied Neuroscience, held at the University of Cyprus. Morfeas’s poster presentation showcased our ongoing randomized, double-blind, placebo-controlled clinical trial investigating the efficacy of ketamine in treating negative affect and preventing relapse […]

Read More »

Dr. Zanos was invited to give a talk at the Foundation for Research and Technology in Crete about our ongoing studies on ketamine and opioid use disorders

No Comments
| News

Dr. Panos Zanos was recently invited to present at the Foundation for Research and Technology (FORTH) in Crete, where he shared insights into the Zanos Lab’s pioneering work on ketamine and opioid use disorders. His presentation focused on the PROUD study, a groundbreaking clinical trial investigating the therapeutic potential of ketamine in individuals with opioid […]

Read More »

Morfeas Koumas awarded a FENS/IBRO-PERC Fellowship for advanced training in Barcelona

No Comments
| News

We are delighted to announce that our first-year Ph.D. student, Morfeas Koumas (BSc, MSc), has been awarded the FENS/IBRO-PERC Fellowship to conduct a six-week research exchange at the University of Barcelona. Morfeas will train under the mentorship of Dr. Jordi Bonaventura, an expert in addiction neuroscience and behavioral pharmacology. This fellowship represents a crucial step […]

Read More »

Dr. Andria Michael presents research on ketamine-based therapies for opioid relapse prevention

No Comments
| News

Dr. Andria Michael, a postdoctoral researcher in the Zanos Lab, recently represented our laboratory at the 13th International Multithematic Scientific Bio-Medical Congress in Cyprus, at the European University Cyprus School of Medicine. Her presentation highlighted groundbreaking work on novel pharmacotherapies for preventing relapse to opioid use disorders during abstinence. The research focuses on ketamine, a […]

Read More »

New pre-print: VirTarget framework reveals how Multiple Sclerosis immunotherapies engage with Epstein-Barr Virus-driven disease mechanisms

No Comments
| News

The AI & Systems Bioinformatics Unit of the Translational Neuropharmacology Lab has released a new preprint introducing VirTarget, the first virus-informed pharmacogenomics framework designed to systematically evaluate how multiple sclerosis (MS) immunotherapies interact with Epstein-Barr virus (EBV)-driven pathogenesis. While EBV is increasingly recognized as a central driver of MS, current immunotherapies are prescribed without considering […]

Read More »

New preprint: VirTrack framework reveals stage-specific EBV pathogenesis in Multiple Sclerosis

No Comments
| News

We’re excited to share our latest preprint, “VirTrack: A Framework for Inferring Viral Influence on Disease-Associated Transcriptomes — Clinical Type-Specific Epstein–Barr Virus Pathogenesis in Multiple Sclerosis,” now available on bioRxiv. This work, led by Dr. Anna Onisiforou, Head of our AI & Systems Bioinformatics Unit, represents a major advance in understanding how Epstein–Barr virus (EBV) […]

Read More »

Translational Neuropharmacology Lab presents on novel therapies for brain disorders

No Comments
| News

Dr. Panos Zanos recently delivered a presentation on novel pharmacological therapies for brain diseases at the Ierokipio University in Paphos, Cyprus. The Ierokipio University is a lifelong learning initiative that brings scientific knowledge to the general public, fostering dialogue between researchers and community members on important health and medical topics. The presentation provided an overview […]

Read More »

Dr. Zanos was invited and presented on antidepressant mechanisms of action of ketamine and other rapid-acting antidepressants at the 6th German-Cypriot Psychotherapy Conference

No Comments
| News

Dr. Panos Zanos delivered an invited presentation at the 6th German-Cypriot Conference Psychotherapy Dialogues, titled “Neurobiology of Depression: Traditional & Rapid-acting Pharmacotherapies.” The presentation addressed a critical challenge in psychiatry: conventional antidepressants require three to four weeks to produce therapeutic effects, with approximately thirty percent of patients failing to respond. Dr. Zanos explored the neurobiological […]

Read More »

Posts pagination

Previous 1 2 3 4 … 12 Next

Recent Posts

  • New Publication in Neuroscience & Biobehavioral Reviews: A Hierarchical Framework for Nociplastic Pain September 11, 2026
  • Dr. Charalambous presents brain aging research at AAIC 2026 July 13, 2026
  • Mapping the Epstein-Barr Virus-Multiple Sclerosis Axis: Dr. Anna Onisiforou presents VirTrack and VirTarget at the FENS Forum 2026 July 9, 2026
  • Dr. Panoutsopoulos presents research on ketamine and early neurodevelopment at FENS Forum 2026 July 8, 2026
  • Research spotlight: Unraveling the role of Eukaryotic Elongation Factor 2 Kinase in the antidepressant mechanism of (2R,6R)-hydroxynorketamine June 4, 2026

Navigation

  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Translational Neuropharmacology Lab (Zanos Lab) 2026 . Powered by WordPress